# Apexigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apexigen

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.apexigen.com
- Total disclosed funding: $199M
- Latest round: Series C (Mar 24, 2020)
- Investors on record: 11

## About

Apexigen, Inc. develops innovative immuno-oncology therapeutics, focusing on antibody-based products designed to enhance cancer treatment efficacy and improve patient outcomes.Founded in 2010 in San Carlos, US, Apexigen, Inc. specializes in immuno-oncology. The company was acquired by Pyxis Oncology, Inc. on May 24, 2023, for USD 16 mn. The CEO, Xiaodong Yang, leads the firm, which has closed 9 deals overall. Apexigen’s headquarters are in San Carlos, California.Apexigen specializes in developing immuno-oncology therapeutics, primarily focusing on antibody-based products. Their lead product targets the immune checkpoint protein PD-1, aiming to activate the immune response against tumors in patients with various cancers. Their products are marketed to healthcare providers in North America, Europe, and parts of Asia, addressing an increasing need for effective cancer therapies.Apexigen's revenue model is based on strategic partnerships for developing and commercializing therapeutics. The company engages in B2B transactions with pharmaceutical firms and research institutions, focusing on milestone payments and royalties from sales of its antibody-based therapies.Following its acquisition by Pyxis Oncology, Inc., Apexigen will support the expansion of its clinical pipeline into Phase 2 for select solid tumor types, leveraging its immuno-oncology expertise. The latest funding will facilitate this strategic push, aimed at enhancing their clinical offerings in the immuno-oncology sector. Specific new products are currently under development, although no detailed release dates have been disclosed.

## Funding rounds

- Series C, Mar 24, 2020, $65M — Decheng Capital, Oceanpine Capital
- Series C, Nov 27, 2019, $46M — Decheng Capital, Oceanpine Capital
- Series B, Aug 8, 2018, $15M — Decheng Capital
- Series C, Jun 6, 2018, $37M — SV Tech Ventures, Virtus Inspire Ventures, 3E Bioventures Capital
- Series C, Dec 5, 2017, $21M — SV Tech Ventures, Virtus Inspire Ventures, 3E Bioventures Capital
- Series A, Apr 30, 2013, $15M — CDIB Capital Group, Sycamore Ventures, Themes Investment Partners, Amkey Ventures, Kenson Ventures, WSR Capital

## Investors

- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series A
- Sycamore Ventures (https://capitalatlas.ai/funds/sycamore-ventures) — Series A
- Themes Investment Partners (https://capitalatlas.ai/funds/themes-investment-partners) — Series A
- Amkey Ventures (https://capitalatlas.ai/funds/amkey-ventures) — Series A
- Kenson Ventures (https://capitalatlas.ai/funds/kenson-ventures) — Series A
- WSR Capital (https://capitalatlas.ai/funds/wsr-capital) — Series A
- SV Tech Ventures (https://capitalatlas.ai/funds/sv-tech-ventures) — Series C
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series C
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C